Waters Corporation (ETR:WAZ)
Germany · Delayed Price · Currency is EUR | Market Cap | 41.71B +115.0% |
| Revenue (ttm) | 4.98B +80.7% |
| Net Income | 87.63M -84.8% |
| EPS | 1.01 -89.4% |
| Shares Out | n/a |
| PE Ratio | 425.58 |
| Forward PE | 29.30 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 428.20 |
| Previous Close | 424.20 |
| Day's Range | 428.20 - 430.60 |
| 52-Week Range | 299.00 - 432.40 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2026 |
About Waters
Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. The company operates through two segments, Waters and TA. The company designs, manufactures, sells, and services liquid chromatography, as well as mass spectrometry (MS) technology systems and supports products, including chromatography columns, and other consumable products. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, p... [Read more]
Financial Performance
In 2025, Waters's revenue was $3.17 billion, an increase of 6.99% compared to the previous year's $2.96 billion. Earnings were $642.63 million, an increase of 0.75%.
Financial numbers in USD Financial StatementsNews
Waters announces FDA 510(k) clearance of ready-to-use flow cytometry tests
Waters (WAT) announced that the BD OneFlow LST Test and BD OneFlow B-CLPD T1 Test have received U.S. FDA 510(k) clearance. This clearance enables commercialization in the U.S. and provides…
Waters Achieves FDA 510(k) Clearance for Ready-to-Use Flow Cytometry Clinical Tests for Leukemia and Lymphoma
BD OneFlow™ LST and BD OneFlow™ B-CLPD T1 Tests now FDA 510(k)-cleared in U.S. for identifying B-cell non-Hodgkin lymphoma (NHL) Delivers 96.3% sensitivity and 98.2% specificity1 in identifying chroni...
Waters price target raised to $530 from $480 at Piper Sandler
Piper Sandler raised the firm’s price target on Waters (WAT) to $530 from $480 and keeps an Overweight rating on the shares.
Waters price target raised to $530 from $515 at TD Cowen
TD Cowen raised the firm’s price target on Waters (WAT) to $530 from $515 and keeps a Buy rating on the shares. The firm updated its model following strong Q3…
Waters price target raised to $525 from $475 at RBC Capital
RBC Capital raised the firm’s price target on Waters (WAT) to $525 from $475 and keeps an Outperform rating on the shares after its Q3 earnings beat and guidance raise.
Waters price target raised to $500 from $460 at KeyBanc
KeyBanc raised the firm’s price target on Waters (WAT) to $500 from $460 and keeps an Overweight rating on the shares. The firm notes Waters posted a top- to bottom-line…
Waters price target raised to $470 from $435 at JPMorgan
JPMorgan analyst Casey Woodring raised the firm’s price target on Waters (WAT) to $470 from $435 and keeps a Neutral rating on the shares.
Waters price target raised to $536 from $470 at Citi
Citi raised the firm’s price target on Waters (WAT) to $536 from $470 and keeps a Buy rating on the shares.
Waters price target raised to $470 from $420 at Stifel
Stifel analyst Daniel Arias raised the firm’s price target on Waters (WAT) to $470 from $420 and keeps a Hold rating on the shares.
Waters price target raised to $504 from $495 at Baird
Baird analyst Catherine Ramsey Schulte raised the firm’s price target on Waters (WAT) to $504 from $495 and keeps an Outperform rating on the shares. The firm updated its model…
Waters price target raised to $530 from $500 at Barclays
Barclays raised the firm’s price target on Waters (WAT) to $530 from $500 and keeps an Overweight rating on the shares following the Q3 beat.
Waters Earnings Call Transcript: Q3 2026
Q3 revenue reached $1.767B, with organic growth of 10% in constant currency and adjusted EPS up 21% to $4.10. FY26 revenue guidance rose $43M at midpoint, while the 2027 framework points to mid-single-digit-plus growth and 100 bps of margin expansion.
Waters Earnings release: Q3 2026
Waters released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
Waters Slides: Q3 2026
Waters has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 3, 2026.
Waters Quarterly report: Q3 2026
Waters has published its Q3 2026 quarterly earnings report on November 3, 2026.
Waters raises FY26 adjusted EPS view to $14.60-$14.70 from $14.45-$14.65
Consensus $14.58. Raises FY26 revenue view to $6.48B-$6.5B from $6.42B-$6.48B, consensus $6.46B. Batra continued, “Thanks to the hard work of our teams, we are delivering ahead of schedule on our…
Waters reports Q3 adjusted EPS $4.10, consensus $4.00
Reports Q3 revenue $1.77B, consensus $1.75B. “Our team delivered exceptional results led by best-in-class consumables growth across both our Analytical Sciences and Biosciences divisions, as strong ex...
Waters sees Q4 adjusted EPS $4.58-$4.68, consensus $4.67
Sees Q4 revenue $1.8B-$1.82B, consensus $1.79B. The company said, “The Company expects fourth quarter 2026 organic constant currency revenue growth to be in the range of 7.0% to 9.0%. Including…
Waters acquires MOBILion Systems, terms undisclosed
Waters (WAT) announced that it has acquired MOBILion Systems. The acquisition broadens Waters’ entry into the proteomics market, pairing SLIM’s separation power with Waters’ Xevo MRT MS speed and reso...
Waters Corporation (NYSE: WAT) Reports Third Quarter 2026 Financial Results
Company to Provide Starting 2027 Growth Framework on Earnings Conference Call Third Quarter 2026 Highlights Total reported revenue of $1.767 billion exceeded guidance midpoint by $14 million, led by o...
Waters Acquires MOBILion Systems, Bringing Advanced Ion-Mobility Separation to its Mass Spectrometry Portfolio with the Speed and Resolution AI Workflows Require for Proteomics Biomarker Discovery
Adds MOBILion's breakthrough SLIM high-resolution ion mobility technology, which separates molecules by size, shape and charge in milliseconds, complementing Waters' industry leading mass spectrometry...
Waters Launches AI-Powered Peak Integration Expanding its Suite of Premium AI Subscription Capabilities for Empower Software
Advances Waters' strategy to bring trusted AI, ML, and automation capabilities to the 500,000 Empower™ Software users who run the world's regulated chromatography labs and support the release of over ...
Waters, Labcorp partner to expand access to cervical cancer screening
Labcorp (LH) and Waters (WAT) announced a partnership to expand access to the FDA-approved BD Onclarity HPV Assay through Labcorp’s nationwide laboratory network beginning in late 2026. Cervical cance...
Waters, Labcorp partner to expand access to cervical screening
Labcorp (LH) and Waters (WAT) announced a partnership to expand access to the FDA-approved BD Onclarity HPV Assay through Labcorp’s nationwide laboratory network beginning in late 2026. Cervical cance...
Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026
Labcorp intends to be the first commercial laboratory to offer FDA-approved HPV testing with the BD Onclarity™ HPV Assay across clinician-collected and self-collected screening options in clinic, pati...